Trial Profile

A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naive Subjects

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/darunavir (Primary) ; Rilpivirine (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms PREZENT

Most Recent Events

27 Jul 2018 Results presented at the 22nd International AIDS Conference
27 Oct 2017 Results of a substudy assessing the cerebrospinal fluid concentrations, efficacy and neurocognitive effects of darunavir/cobicistat and Rilpivirine, presented at the 16th European AIDS Conference.
27 Oct 2017 Status changed to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com